Search research articles
Contact Us
Filters
Showing results (11-20 of 14) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 14 results.
European Journal of Medicinal Chemistry
|
September 9, 2008
Design, synthesis, structure-activity relationship and antibacterial activity series of novel imidazo fused quinolone carboxamides
G Venkat Reddy, S Ravi Kanth, D Maitraie, et al.
Nature Communications
|
January 6, 2022
Author Correction: Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling
Carla Danussi, Promita Bose, Prasanna T Parthasarathy, et al.
Nature Communications
|
March 15, 2018
Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling
Carla Danussi, Promita Bose, Prasanna T Parthasarathy, et al.
Plos One
|
July 12, 2013
Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients
Mohideen S Jawahar, Vaithilingam V Banurekha, Chinnampedu N Paramasivan, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 14) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 14 results.
European Journal of Medicinal Chemistry
|
September 9, 2008
Design, synthesis, structure-activity relationship and antibacterial activity series of novel imidazo fused quinolone carboxamides
G Venkat Reddy, S Ravi Kanth, D Maitraie, et al.
Nature Communications
|
January 6, 2022
Author Correction: Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling
Carla Danussi, Promita Bose, Prasanna T Parthasarathy, et al.
Nature Communications
|
March 15, 2018
Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling
Carla Danussi, Promita Bose, Prasanna T Parthasarathy, et al.
Plos One
|
July 12, 2013
Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients
Mohideen S Jawahar, Vaithilingam V Banurekha, Chinnampedu N Paramasivan, et al.
Page
of 2